These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27753599)

  • 1. External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation.
    Spitzer E; Hadorn S; Zanchin T; Yamaji K; Moschovitis A; Pilgrim T; Stortecky S; Jüni P; Heg D; Windecker S; Räber L
    EuroIntervention; 2016 Oct; 12(9):1135-1143. PubMed ID: 27753599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiography-guided Multivessel Percutaneous Coronary Intervention Versus Ischemia-guided Percutaneous Coronary Intervention Versus Medical Therapy in the Management of Significant Disease in Non-Infarct-related Arteries in ST-Elevation Myocardial Infarction Patients With Multivessel Coronary Disease.
    Perera D; Crake T; Lee V
    Crit Pathw Cardiol; 2018 Jun; 17(2):77-82. PubMed ID: 29768315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial).
    Gennaro G; Brener SJ; Redfors B; Kirtane AJ; Généreux P; Maehara A; Neunteufl T; Metzger DC; Mehran R; Gibson CM; Stone GW
    Am J Cardiol; 2016 Oct; 118(8):1097-1104. PubMed ID: 27553094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with aspiration thrombectomy Vs. Conventional percutaneous coronary intervention during ST-segment elevation myocardial infarction.
    Dominguez AC; Bittl JA; El-Hayek G; Contreras E; Tamis-Holland JE
    Catheter Cardiovasc Interv; 2016 Jun; 87(7):1203-10. PubMed ID: 26699698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of arterial access site selection on outcomes in primary percutaneous coronary intervention: are the results of randomized trials achievable in clinical practice?
    Mamas MA; Ratib K; Routledge H; Neyses L; Fraser DG; de Belder M; Ludman PF; Nolan J;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):698-706. PubMed ID: 23769648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
    Tatlisu MA; Kaya A; Keskin M; Uzman O; Borklu EB; Cinier G; Hayiroglu MI; Eren M
    Coron Artery Dis; 2016 Nov; 27(7):543-50. PubMed ID: 27341666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial.
    Schoos MM; De Luca G; Dangas GD; Clemmensen P; Ayele GM; Mehran R; Stone GW
    EuroIntervention; 2016 Oct; 12(9):1144-1153. PubMed ID: 27753600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials.
    Taniwaki M; Stefanini GG; Räber L; Brugaletta S; Cequier A; Heg D; Iñiguez A; Kelbæk H; Serra A; Ostoijic M; Hernandez-Antolin R; Baumbach A; Blöchlinger S; Jüni P; Mainar V; Sabate M; Windecker S
    EuroIntervention; 2015 Aug; 11(4):391-8. PubMed ID: 25042419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction.
    Piccolo R; Galasso G; Eitel I; Dominguez-Rodriguez A; Iversen AZ; Gu YL; Abreu-Gonzalez P; de Smet BJ; Esposito G; Windecker S; Thiele H; Piscione F
    Am J Cardiol; 2016 Dec; 118(12):1798-1804. PubMed ID: 27756477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
    Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial.
    Yu J; Mehran R; Grinfeld L; Xu K; Nikolsky E; Brodie BR; Witzenbichler B; Kornowski R; Dangas GD; Lansky AJ; Stone GW
    Catheter Cardiovasc Interv; 2015 Feb; 85(3):359-68. PubMed ID: 25115966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction.
    Wijnbergen I; Tijssen J; van 't Veer M; Michels R; Pijls NH
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):379-84. PubMed ID: 23553888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Late Cardiac Death and Myocardial Infarction Rates in Women Vs Men With ST-Elevation Myocardial Infarction.
    Burgess SN; Juergens CP; Nguyen TL; Leung M; Robledo KP; Thomas L; Mussap CJ; Zaman SJ; Lo STH; French JK
    Am J Cardiol; 2020 Aug; 128():120-126. PubMed ID: 32650905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
    JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current characteristics and management of ST elevation and non-ST elevation myocardial infarction in the Tokyo metropolitan area: from the Tokyo CCU network registered cohort.
    Miyachi H; Takagi A; Miyauchi K; Yamasaki M; Tanaka H; Yoshikawa M; Saji M; Suzuki M; Yamamoto T; Shimizu W; Nagao K; Takayama M
    Heart Vessels; 2016 Nov; 31(11):1740-1751. PubMed ID: 26758733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
    Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
    JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Total Bilirubin and Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention With Drug-Eluting Stents.
    Chung SR; Yang TH; Shin HC; Jin HY; Seo JS; Jang JS; Kim DK; Kim DS; Seo GW; Song PS; Kim DK; Kim KH; Seol SH; Kim DI; Cho YK; Yoon HJ; Nam CW; Hur SH; Kim U; Park JS; Kim YJ
    Circ J; 2016 May; 80(6):1437-44. PubMed ID: 27151334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study.
    Farag M; Spinthakis N; Gue YX; Srinivasan M; Sullivan K; Wellsted D; Gorog DA
    Eur Heart J; 2019 Jan; 40(3):295-305. PubMed ID: 30380032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.